Sign in

You're signed outSign in or to get full access.

PG

Peter Green

Research Analyst at LifeSci Capital, LLC

Peter Green is an Equity Research Associate at LifeSci Capital, specializing in equity research within the life sciences and biotechnology sectors. He collaborates with senior analysts to cover emerging biotech companies, supporting investment research and analysis for firms engaged in innovative medical therapies and technologies. Green began his career in financial analysis and joined LifeSci Capital as an Associate, leveraging his expertise in data analysis and sector knowledge; prior professional experience is not publicly documented, suggesting LifeSci Capital as his primary financial services employer to date. He holds appropriate regulatory credentials for equity research roles, including FINRA registration and securities licensing, and is recognized within the firm for detailed company coverage and rigorous analytical work.

Peter Green's questions to Kura Oncology (KURA) leadership

Question · Q2 2025

Peter Green, on for Charles Zhou, asked for details on patient baselines for the upcoming KO-2806 data in RCC at ESMO and inquired about plans for additional data disclosures for Zifdomenib in the relapsed/refractory NPM1 setting.

Answer

Chief Medical Officer Dr. Mollie Leoni stated that while she could not preempt the ESMO abstract, the RCC data would include a typical, varied Phase 1 patient population. She also confirmed that a publication for the Zifdomenib monotherapy data should be expected in the coming months.

Ask follow-up questions

Fintool

Fintool can predict Kura Oncology logo KURA's earnings beat/miss a week before the call